

The importance of biomarker testing in mCRC

ESMO guidelines recommend that 'Tumour *BRAF* mutation status should be assessed alongside the assessment of tumour *RAS* mutational status'⁸

Look for the dangerous drivers in mCRC


44%*⁷

RAS mutations

12%*⁶

BRAF mutations

RAS and *BRAF* wild-type



Adapted from: Refs. 6, 7

*This is the maximum; values may vary up to this. ESMO, European Society for Medical Oncology.

6. VanCutsem E, *et al. Ann Oncol* 2016;27:1386–422. 7. Kafatos G, *et al. Biomark Med* 2017;11:751–60.

8. Cervantes A, *et al. Ann Oncol* 2023;34(1):10-32.

© 2023 Pierre Fabre, all rights reserved.

Pierre Fabre Singapore Pte. Ltd. 96 Robinson Road, SIF Building, #14-03, Singapore 068899.

SG_BMC_2306_04. Material Approved: June 2023



Pierre Fabre